Stockreport

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader [Read more]